Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Mol Carcinog. 2012 Aug 21;53(1):38–48. doi: 10.1002/mc.21946

Figure 2. Pre-miR-24-2 decreases PKCα-mediated cellular survival in vitro and in vivo.

Figure 2

(A) MCF-7-vector and -miR-24-2 cells were grown in 5% DMEM for 48 hours prior to treatment with TNF (1ng/mL), PMA (29ng/mL), or TNF + PMA for 24 hours. Cells were then treated with MTT for 4 hours and lysed. Treatment groups were normalized as % vehicle treated cell line. * Significantly different from vehicle treated vector, p < 0.05. ** Significantly different from vehicle treated vector, p < 0.001. Error bars represent SEM, n = 5 independent biological repeats. (B) 5 × 106 MCF-7-vector or −miR-24-2 cells were injected into the mammary fat pad of SCID/beige female mice. Final tumor volume and tumor formation was obtained at day 52. (A) Final tumor volume. n=10 for MCF-7-vector cells and n=6 MCF-7-miR-24-2 cells. * Significantly different from vector, p < 0.05. Error bars represent SEM. (C) Final tumor formation of n=10 injections for MCF-7-vector and-miR-24-2 injected mice.